ZD1839 (Iressa™) and concurrent chemo-radiation in patients with locally advanced non small cell lung cancer

Study identifier:D7913C00073

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I Trial to evaluate ZD1839(Iressa™) and concurrent chemo-radiation in patients with locally advanced non small cell lung cancer

Medical condition

Non Small Cell Lung Carcinoma

Phase

Phase 1

Healthy volunteers

Study drug

Gefitinib, Carboplatin, Paclitaxel

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Jul 2002

Primary Completion Date: -

Study Completion Date: 01 Oct 2005

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

East Melbourne, Victoria, Australia

Location

Research Site

Woolloonabba, Queensland, Australia

Arms	Assigned Interventions

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=598&filename=CSR-D7913C00073.pdf
Download
CSR-D7913C00073.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Australia Pty Ltd

+61 2 9978 3500

Investigators

Principal Investigator

AstraZeneca Australia Medical Director

AstraZeneca

ZD1839 (Iressa™) and concurrent chemo-radiation in patients with locally advanced non small cell lung cancer

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Research Site

Research Site

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=598&filename=CSR-D7913C00073.pdf

CSR-D7913C00073.pdf

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator